In terms of revenue, global oncology drugs market was valued at US$ 119 billion in 2020. The introduction and approval of anti-PD-1 agents’ nivolumab and pembrolizumab for NSCLC has bought a new era for the cancer industry.

The global Oncology Drugs market research is an intelligence report announced by Absolute Markets Insights. The erudite market study provides insightful data for readers to help them in making informed business decisions. Primary and secondary research methodologies have also been used to discover the correct and applicable data of Oncology Drugs market. Effective business strategies of key market players and of new startup industries are also studied thoroughly to provide extensive market knowledge. The report makes use of an effective analysis technique such as SWOT and Porter’s five analysis to present its accurate results on the market.

The study further presents the details on financial attributes such as pricing structures, shares and profit margins. Top level companies profiled in this report includes F. Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc., Eli Lilly and Company, Novartis AG, Pfizer Inc., Bayer AG, AstraZeneca, Merck & Co., Inc., CELGENE CORPORATION and Polaris Pharmaceuticals. The competitive landscape of the Oncology Drugs market has been provided by analyzing different successful and startups industries. The economic aspects of the businesses have been presented by using facts and figures.

For More Information Click@

The number of patients receiving single-agent chemotherapy decreased considerably in the recent past and the patients who received EGFR-TKI based therapy also reduced substantially. Single drug therapies coupled with monoclonal antibodies against programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) have shown little efficacy in patients suffering from metastatic breast cancer. The same is low number of tumour-infiltrating lymphocytes, found in most of the breast cancers. As a result, the development of combinations of molecularly targeted therapies and immunotherapy have proven to be a great success.

The China and United States hold the leading positions in the cancer cell therapy pipeline. The number for the same are 439 and 305 agents respectively. Majority of the drugs developed in the United States are at pre-clinical stage, whereas the drugs that are being developed in China are at clinical stages. In August, 2019, the U.S. FDA granted approval to Rozlytrek. This drug is for adoslescents and adult who are suffering from genetic cancer defects. This drug got approval for treating diseases like NTRK (neurotrophic tyrosine receptor kinase) gene fusion. The drug has a unique ability to shrink tumors and has been evaluated in four clinical trials, studying the adults who are suffering from NTRK fusion-positive tumors.

Oncology Drugs Market Segmentation:

By Indication

  • Breast Cancer
  • Prostate Cancer
  • Basal Cell Cancer
  • Skin Cancer (Non-Melanoma)
  • Colorectal cancer
  • Lung Cancer
  • Renal Cancer
  • Bladder Cancer
  • Lymphoma
  • Others

By Treatment

  • Drug Therapies
    • Antimetabolites
    • Antitumor Antibiotics
    • Asparagine-Specific Enzymes
    • Bisphosphonates & Biosimilars
    • DNA-Damaging Agents (Antineoplastics) and Alkylating Agents
    • Inhibitors
      • DNA-Repair Enzyme Inhibitors
      • Histone Deacetylase Inhibitors
      • Janus-Associated Kinase (JAK) Inhibitors
      • Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)
      • Proteasome Inhibitors
      • Tyrosine Kinase Inhibitors
      • PD-1 and PD-L1 inhibitors
      • Others
    • Monoclonal Antibodies
    • Others
  • Surgery
    • Open Surgery
    • Minimally Invasive Surgery
  • Radiation Therapy
  • Chemotherapy
  • Immunotherapy
    • Chimeric antigen receptor (CAR) T-cell therapy
    • Cytokine Treatment
    • Donor lymphocyte infusion
    • Monoclonal Antibody Treatment
    • Others
  • Targeted Therapy
  • Hormone Therapy
  • Stem Cell Transplant
    • Autologous stem cell transplantation
    • Allogeneic stem cell transplantation
    • Reduced-Intensity Allogeneic Stem Cell Transplantation
    • Graft-Versus-Host Disease
  • Precision Medicine
  • Others

 By Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America

Contact Us:

Company: Absolute Markets Insights

Email Id:

Phone: IN +917400242424, US +1-510-420-1213

Contact Name: Shreyas Tanna